Clinical Trial

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-07; most recent amendment 2026-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT07122687
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Enrollment 170 participants
Start Date 2025-08-26
Primary Completion 2026-11-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-27